ArticleFrontiers in cardiovascular medicine2022
Changing trends of the disease burden of non-rheumatic valvular heart disease in China from 1990 to 2019 and its predictions: Findings from global burden of disease study.
Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Comparisons of the Burden and Quality of Care of Nonrheumatic Valvular Heart Disease in Asia and Globally.Journal of the American Heart Association · 2026Article
- Comparison of mechanical versus bioprosthetic valve replacement in mitral stenosis surgery.BMC cardiovascular disorders · 2026Article
- Aging China's cardiac challenge: Projected growth of atrial arrhythmia cases and healthcare preparedness through 2045 - A global burden disease analysis.Geriatrics & gerontology international · 2025Article
- Global, regional, and national burden of non-rheumatic valvular heart disease and Its projections to 2035: comprehensive analysis of the global burden of disease study 2019.Frontiers in cardiovascular medicine · 2025Article
- What are the best clinical management strategies for cardiomyopathy? an umbrella review of systematic reviews and meta-analyses.Frontiers in pharmacology · 2025Article
- Global, Regional, and National Burden of Nonrheumatic Valvular Heart Disease and Its Attributable Risk Factors in 204 Countries and Territories, 1990 to 2019: Results From the Global Burden of Disease Study 2019.Journal of the American Heart Association · 2024Article
- Clinical profile, management strategy, and outcomes of patients with prosthetic valve thrombosis.Global cardiology science & practice · 2024Article
- Trends and age-period-cohort effect on the incidence of falls from 1990 to 2019 in BRICS.Heliyon · 2024Article
- Global, regional, and national burdens of atrial fibrillation/flutter from 1990 to 2019: An age-period-cohort analysis using the Global Burden of Disease 2019 study.Journal of global health · 2023Article
- Analysis and comparison of the trends in burden of rheumatic heart disease in China and worldwide from 1990 to 2019.BMC cardiovascular disorders · 2023Article
- Advances in diagnosis and treatment of mechanical hemolysis following percutaneous interventional for valvular heart diseases.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: China has an increasing burden of non-rheumatic valvular heart disease (NRVHD) as the aging of the population is deepening. The aim was to assess the age and sex-specific prevalence and DALYs of NRVHD in China from 1990 to 2019 and to predict the burden in the next 25 years. Methods: The Global Burden of Disease Study (2019) was used to extract the data of age- and sex-specific incidence, mortality, and disability-adjusted life years (DALYs) of NRVHD in China, 1990-2019. We estimated the annual percentage change (EAPC) to access the temporal trends of the disease burden of NRVHD. The R package called Nordpred was used to perform an age-period-cohort analysis to predict the prevalence of NRVHD in the next 25 years. Results: The number of incident cases of NRVHD increased from 93.16 thousand in 1990 to 325.05 thousand in 2019. Overall upward trends were observed in the age-standardized incidence rate (ASIR) from 1990 to 2019. Significant temporal trends in mortality and DALYs of NRVHD were observed. High systolic blood pressure, high sodium diet, and lead exposure were the main driving forces for NRVHD. In the next 25 years, the number of new cases and deaths of NRVHD should continue to increase to 390.64 thousand and 10.0 thousand, respectively. The ASIR should show an upward trend, while the ASMR should show a downward trend among men and women. Conclusion: In China, the overall rates of NRVHD have increased over the past 30 years, and there has been a substantial increase in the burden of NRVHD due to population growth and aging and will continue to increase in the next 25 years. Our results can help shape a multifactorial approach and public policy to reduce the NRVHD burden throughout China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.